SCA
TTOO

STALEY CAPITAL ADVISERS’s T2 Biosystems, Inc TTOO Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio TTOO Stock Details TTOO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed -$116K – 176
2018
Q2 		$116K Buy
+3
New +$114K 0.01% 167

Other funds holding TTOO

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

STALEY CAPITAL ADVISERS's TTOO Position: Q3 2018 in Review

STALEY CAPITAL ADVISERS sold out of T2 Biosystems, Inc (TTOO) in Q3 2018, closing a stake of 3 shares — an estimated $116K sold.

STALEY CAPITAL ADVISERS first reported a position in TTOO in Q2 2018 and held it in 1 quarter. The position peaked at $116K in Q2 2018. 85 funds tracked by Wall St. Rank hold TTOO as of Q3 2018.

  • STALEY CAPITAL ADVISERS reported no remaining T2 Biosystems, Inc position as of Q3 2018 after selling out during the quarter.
  • STALEY CAPITAL ADVISERS sold 3 T2 Biosystems, Inc shares in Q3 2018, an estimated $116K.
  • STALEY CAPITAL ADVISERS first reported a position in T2 Biosystems, Inc in Q2 2018 and held it in 1 quarter.
  • STALEY CAPITAL ADVISERS's T2 Biosystems, Inc position peaked at $116K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q3 2018.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2018, filed 9 Nov 2018.